These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 8622703)

  • 61. Dasatinib: a tyrosine kinase inhibitor for the treatment of chronic myelogenous leukemia and philadelphia chromosome-positive acute lymphoblastic leukemia.
    Steinberg M
    Clin Ther; 2007 Nov; 29(11):2289-308. PubMed ID: 18158072
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Phosphorylation of tyrosine 393 in the kinase domain of Bcr-Abl influences the sensitivity towards imatinib in vivo.
    Miething C; Mugler C; Grundler R; Hoepfl J; Bai RY; Peschel C; Duyster J
    Leukemia; 2003 Sep; 17(9):1695-9. PubMed ID: 12970766
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Differential expression and signaling of CBL and CBL-B in BCR/ABL transformed cells.
    Sattler M; Pride YB; Quinnan LR; Verma S; Malouf NA; Husson H; Salgia R; Lipkowitz S; Griffin JD
    Oncogene; 2002 Feb; 21(9):1423-33. PubMed ID: 11857085
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Effect of herbimycin A, an antagonist of tyrosine kinase, on bcr/abl oncoprotein-associated cell proliferations: abrogative effect on the transformation of murine hematopoietic cells by transfection of a retroviral vector expressing oncoprotein P210bcr/abl and preferential inhibition on Ph1-positive leukemia cell growth.
    Okabe M; Uehara Y; Miyagishima T; Itaya T; Tanaka M; Kuni-Eda Y; Kurosawa M; Miyazaki T
    Blood; 1992 Sep; 80(5):1330-8. PubMed ID: 1515646
    [TBL] [Abstract][Full Text] [Related]  

  • 65. ABL and BCR genes are not imprinted in androgenetic and gynogenetic human tissues.
    Lorberboum-Galski H; Yarkoni S; Nechushtan A; Rachmilewitz J; deGroot N; Hochberg A
    Biochem Biophys Res Commun; 1994 Oct; 204(2):621-7. PubMed ID: 7980523
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Jak2 is involved in c-Myc induction by Bcr-Abl.
    Xie S; Lin H; Sun T; Arlinghaus RB
    Oncogene; 2002 Oct; 21(47):7137-46. PubMed ID: 12370803
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Intrinsic regulation of the interactions between the SH3 domain of p85 subunit of phosphatidylinositol-3 kinase and the protein network of BCR/ABL oncogenic tyrosine kinase.
    Ren SY; Xue F; Feng J; Skorski T
    Exp Hematol; 2005 Oct; 33(10):1222-8. PubMed ID: 16219545
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Crkl is complexed with tyrosine-phosphorylated Cbl in Ph-positive leukemia.
    de Jong R; ten Hoeve J; Heisterkamp N; Groffen J
    J Biol Chem; 1995 Sep; 270(37):21468-71. PubMed ID: 7545163
    [TBL] [Abstract][Full Text] [Related]  

  • 69. The gatekeeper mutation T315I confers resistance against small molecules by increasing or restoring the ABL-kinase activity accompanied by aberrant transphosphorylation of endogenous BCR, even in loss-of-function mutants of BCR/ABL.
    Mian AA; Schüll M; Zhao Z; Oancea C; Hundertmark A; Beissert T; Ottmann OG; Ruthardt M
    Leukemia; 2009 Sep; 23(9):1614-21. PubMed ID: 19369965
    [TBL] [Abstract][Full Text] [Related]  

  • 70. ABL gene fuses BCR during t(20;22) results in Philadelphia-negative, but BCR/ABL-positive chronic myeloid leukemia.
    Ito Y; Shimamoto T; Kuriyama Y; Nakajima A; Sumi M; Watanabe Y; Beppu H; Ohtsubo K; Ohyashiki K
    Leukemia; 2002 May; 16(5):951-2. PubMed ID: 11986960
    [No Abstract]   [Full Text] [Related]  

  • 71. Establishment and characterization of a new Ph1-positive ALL cell line (ALL/MIK) presenting bcr gene rearrangement on bcr-2 and ALL-type bcr/abl transcript: suggestion of in vitro differentiation to monocytoid lineage.
    Higa T; Okabe M; Kunieda Y; Kodama S; Itaya T; Kurosawa M; Sakurada K; Maekawa I; Shoji M; Kasai M
    Leuk Lymphoma; 1994 Jan; 12(3-4):287-96. PubMed ID: 8167560
    [TBL] [Abstract][Full Text] [Related]  

  • 72. A comparative analysis of FISH, RT-PCR, and cytogenetics for the diagnosis of bcr-abl-positive leukemias.
    Cox MC; Maffei L; Buffolino S; Del Poeta G; Venditti A; Cantonetti M; Aronica G; Aquilina P; Masi M; Amadori S
    Am J Clin Pathol; 1998 Jan; 109(1):24-31. PubMed ID: 9426514
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Molecular biology of chronic myeloid leukemia.
    Maru Y
    Int J Hematol; 2001 Apr; 73(3):308-22. PubMed ID: 11345196
    [TBL] [Abstract][Full Text] [Related]  

  • 74. P210 and P190(BCR/ABL) induce the tyrosine phosphorylation and DNA binding activity of multiple specific STAT family members.
    Ilaria RL; Van Etten RA
    J Biol Chem; 1996 Dec; 271(49):31704-10. PubMed ID: 8940193
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Characterization of breakpoint cluster region kinase and SH2-binding activities.
    Afar DE; Witte ON
    Methods Enzymol; 1995; 256():125-9. PubMed ID: 7476425
    [TBL] [Abstract][Full Text] [Related]  

  • 76. BCR/ABL oncoprotein-targeted antitumor activity of antisense oligodeoxynucleotides complementary to bcr/abl mRNA and herbimycin A, an antagonist of protein tyrosine kinase: inhibitory effects on in vitro growth of Ph1-positive leukemia cells and BCR/ABL oncoprotein-associated transformed cells.
    Okabe M; Kunieda Y; Miyagishima T; Kobayashi M; Kurosawa M; Itaya T; Sakurada K; Miyazaki T
    Leuk Lymphoma; 1993 Jul; 10(4-5):307-16. PubMed ID: 7693103
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Tyrosine kinase activity and transformation potency of bcr-abl oncogene products.
    Lugo TG; Pendergast AM; Muller AJ; Witte ON
    Science; 1990 Mar; 247(4946):1079-82. PubMed ID: 2408149
    [TBL] [Abstract][Full Text] [Related]  

  • 78. The Src family kinase Hck interacts with Bcr-Abl by a kinase-independent mechanism and phosphorylates the Grb2-binding site of Bcr.
    Warmuth M; Bergmann M; Priess A; Häuslmann K; Emmerich B; Hallek M
    J Biol Chem; 1997 Dec; 272(52):33260-70. PubMed ID: 9407116
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Quantification of change in phosphorylation of BCR-ABL kinase and its substrates in response to Imatinib treatment in human chronic myelogenous leukemia cells.
    Liang X; Hajivandi M; Veach D; Wisniewski D; Clarkson B; Resh MD; Pope RM
    Proteomics; 2006 Aug; 6(16):4554-64. PubMed ID: 16858728
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Inactivation of wild-type BCR/ABL tyrosine kinase in hematopoietic cells by mild hyperthermia.
    Jain SK; de Aos I; Inai Y; Liu F; Varticovski L
    Leukemia; 2000 May; 14(5):845-52. PubMed ID: 10803516
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.